Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2011

01-04-2011 | Epidemiology

Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis

Authors: Ni Li, Xiaofeng Bi, Yawei Zhang, Ping Zhao, Tongzhang Zheng, Min Dai

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Login to get access

Abstract

Despite an increase in the number of molecular epidemiological studies conducted in recent years to evaluate the association between HPV infection and risk of breast carcinoma, the studies remain inconclusive. Here, a meta-analysis was conducted to estimate the prevalence of HPV in breast carcinoma and test the association. Studies on HPV DNA detection in sporadic breast carcinoma in female using polymerase chain reaction were included. Information on overall and type-specific (HPV 6, 11, 16, 18, 31, 33, 35, 45 and 51) HPV prevalence were required, plus detailed descriptions of study populations, HPV DNA source, publication calendar period and PCR primers used for HPV DNA detection and typing. We revealed that 24.49% of the breast carcinoma cases were associated with HPV, 32.42% occurred in Asia and 12.91% in Europe. The four most commonly identified HPV types, in the order of decreased prevalence, were HPV33, 18, 16, and 35. The detection of HPV was mostly influenced by publication calendar period and PCR primers used. In addition, the analysis of ten case–control studies containing 447 breast carcinoma cases and 275 controls showed a significant increase in breast carcinoma risk with HPV positivity (OR = 3.63, 95% CI = 1.42–9.27). These results suggest that it’s difficult to rule out the possibility of the association of HPV and breast carcinoma at present according to available publication proofs.
Appendix
Available only for authorised users
Literature
1.
Munoz N (2000) Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19:1–5PubMedCrossRef
2.
IARC (2007) Human papillomaviruses. IARC Monogr Eval Carcinog.Risks Hum, Geneva
3.
Band V, Zajchowski D, Kulesa V et al (1990) Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci USA 87:463–467PubMedCrossRef
4.
Ong K, Koay ES, Putti TC (2009) Detection of cutaneous HPV types 4 and 24 DNA sequences in breast carcinoma in Singaporean women of Asian ancestry. Pathology 41:436–442PubMedCrossRef
5.
Akil N, Kassab A, Yasmeen A et al (2008) High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 99:404–407PubMedCrossRef
6.
de Cremoux P, Thioux M, Lebigot I et al (2008) No evidence of human papillomavirus DNA sequences in invasive breast carcinoma. Breast Cancer Res Treat 109:55–58PubMedCrossRef
7.
Kroupis C, Markou A, Vourlidis N et al (2006) Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. Clin Biochem 39:727–731PubMedCrossRef
8.
Kan CY, Iacopetta BJ, Lawson JS et al (2005) Identification of human papillomavirus DNA gene sequences in human breast cancer. Br J Cancer 93:946–948PubMedCrossRef
9.
de Villiers EM, Sandstrom RE, zur Hausen H et al (2005) Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. Breast Cancer Res 7:1–11CrossRef
10.
Liu Y, Klimberg VS, Andrews NR et al (2001) Human papillomavirus DNA is present in a subset of unselected breast cancers. J Hum Virol 4:329–334PubMed
11.
Yu Y, Morimoto T, Sasa M et al (1999) HPV33 DNA in premalignant and malignant breast lesions in Chinese and Japanese populations. Anticancer Res 19:5057–5061PubMed
12.
Di Lonardo A, Venuti A, Marcante ML (1992) Human papillomavirus in breast cancer. Breast Cancer Res Treat 21:95–100PubMedCrossRef
13.
Bratthauer GL, Tavassoli FA, O’Leary TJ (1992) Etiology of breast carcinoma: no apparent role for papillomavirus types 6/11/16/18. Pathol Res Pract 188:384–386PubMed
14.
Li T, Lu ZM, Guo M et al (2002) p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95:2571–2576PubMedCrossRef
15.
Wrede D, Luqmani YA, Coombes RC et al (1992) Absence of HPV 16 and 18 DNA in breast cancer. Br J Cancer 65:891–894PubMedCrossRef
16.
Wazer DE, Liu XL, Chu Q et al (1995) Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci USA 92:3687–3691PubMedCrossRef
17.
Damin AP, Karam R, Zettler CG et al (2004) Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat 84:131–137PubMedCrossRef
18.
Heng B, Glenn WK, Ye Y et al (2009) Human papilloma virus is associated with breast cancer. Br J Cancer 101:1345–1350PubMedCrossRef
19.
Tsai JH, Tsai CH, Cheng MH et al (2005) Association of viral factors with non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid tumor tissues. J Med Virol 75:276–281PubMedCrossRef
20.
de Leon DC, Montiel DP, Nemcova J et al (2009) Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients. BMC Cancer 9:26–32PubMedCrossRef
21.
Mendizabal-Ruiz AP, Morales JA, Ramirez-Jirano LJ et al (2009) Low frequency of human papillomavirus DNA in breast cancer tissue. Breast Cancer Res Treat 114:189–194PubMedCrossRef
22.
Khan NA, Castillo A, Koriyama C et al (2008) Human papillomavirus detected in female breast carcinomas in Japan. Br J Cancer 99:408–414PubMedCrossRef
23.
Gumus M, Yumuk PF, Salepci T et al (2006) HPV DNA frequency and subset analysis in human breast cancer patients’ normal and tumoral tissue samples. J Exp Clin Cancer Res 25:515–521PubMed
24.
Gopalkrishna V, Singh UR, Sodhani P et al (1996) Absence of human papillomavirus DNA in breast cancer as revealed by polymerase chain reaction. Breast Cancer Res Treat 39:197–202PubMedCrossRef
25.
Kulka J, Kovalszky I, Svastics E et al (2008) Lymphoepithelioma-like carcinoma of the breast: not Epstein-Barr virus-, but human papilloma virus-positive. Hum Pathol 39:298–301PubMedCrossRef
26.
Czerwenka K, Heuss F, Hosmann JW et al (1996) Human papilloma virus DNA: a factor in the pathogenesis of mammary Paget’s disease? Breast Cancer Res Treat 41:51–57PubMedCrossRef
27.
Aceto GM, Solano AR, Neuman MI et al (2009) High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer. Breast Cancer Res Treat 122:671–683PubMedCrossRef
28.
Hennig EM, Suo Z, Thoresen S et al (1999) Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res Treat 53:121–135PubMedCrossRef
29.
Widschwendter A, Brunhuber T, Wiedemair A et al (2004) Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol 31:292–297PubMedCrossRef
30.
Yu Y, Morimoto T, Sasa M et al (2000) Human papillomavirus type 33 DNA in breast cancer in Chinese. Breast Cancer 7:33–36PubMedCrossRef
31.
Schiffman M, Clifford G, Buonaguro FM et al (2009) Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 1:4–8
32.
Lindel K, Forster A, Altermatt HJ et al (2007) Breast cancer and human papillomavirus (HPV) infection: no evidence of a viral etiology in a group of Swiss women. Breast 16:172–177PubMedCrossRef
33.
Di Lonardo A, Venuti A, Marcante ML et al (1992) Human papillomavirus in breast cancer. Breast Cancer Res Treat 21:95–100PubMedCrossRef
34.
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
35.
DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114PubMedCrossRef
36.
Lau J, Ioannidis JP, Schmid CH et al (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826PubMed
37.
Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed
38.
Begg CB, Mazumdar M et al (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRef
39.
Li N, Franceschi S, Howell-Jones R et al (2010) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. doi:10.​1002/​ijc.​25396
40.
Clifford G, Franceschi S (2008) Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 122:1684–1685PubMedCrossRef
Metadata
Title
Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis
Authors
Ni Li
Xiaofeng Bi
Yawei Zhang
Ping Zhao
Tongzhang Zheng
Min Dai
Publication date
01-04-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1128-0

Other articles of this Issue 2/2011

Breast Cancer Research and Treatment 2/2011 Go to the issue

Review

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

Preclinical study

Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors

Clinical trial

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

Clinical trial

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer

Brief Report

Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy

Clinical trial

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits